ΔF508 mutation increases conformational flexibility of CFTR protein

Journal of Cystic Fibrosis

Volumn 7, Issue 4, 2008, Pages 295-300

  Wieczorek, G ^a   Zielenkiewicz, P ^b  

^a INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^b UNIVERSITY OF WARSAW   (Poland)

Author keywords

CFTR; Cystic fibrosis; Molecular dynamics; Principal component analysis

Indexed keywords

PHENYLALANINE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CELL SURFACE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; CYSTIC FIBROSIS; EPITHELIUM CELL; FOURIER TRANSFORMATION; GENE DELETION; GENE MUTATION; HOUSEKEEPING GENE; HUMAN; HYDROPHOBICITY; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; PATHOGENESIS; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; WILD TYPE; CHEMISTRY; GENETICS; STRUCTURE ACTIVITY RELATION;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; PRINCIPAL COMPONENT ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46749137537     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2007.11.008     Document Type: Article

References (34)

1. Riordan J.R., Rommens J.M., Kerem B., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989) 1066-1073
2. Rommens J.M., Iannuzzi M.C., Kerem B., et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245 (1989) 1059-1065
3. Piserchio A., Fellows A., Madden D.R., and Mierke D.F. Association of the cystic fibrosis transmembrane regulator with cal: structural features and molecular dynamics. Biochemistry 44 (2005) 16158-16166
4. Lewis H.A., et al. Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J Biol Chem 280 (2005) 1346-1353
5. Kopito R.R. Biosynthesis and degradation of CFTR. Physiol Rev 79 (1999) 167-173
6. Ward C.L., Omura S., and Kopito R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83 (1995) 121-127
7. Cheng J., Wang H., and Guggino W.B. Modulation of mature cystic fibrosis transmembrane regulator protein by the pdz domain protein cal. J Biol Chem 279 (2004) 1892-1898
8. Berman H.M., Westbrook J., Feng Z., et al. The protein data bank. Nucleic Acids Res 28 (2000) 235-242
9. Xiang Z., and Honig B. Extending the accuracy limits of prediction for side-chain conformations. J Mol Biol 311 (2001) 421-430
10. Xiang Z., Cinque C.S., and Honig B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. PNAS 99 (2002) 7432-7437
11. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26 (1993) 283-291
12. Kaminski G.A., Friesner R.A., Tirado-Rives J., and Jorgensen W.L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105 (2001) 6474-6487
13. Berendsen H.J.C., van der Spoel D., and van Drunen R. Gromacs: a message-passing parallel molecular dynamics implementation. Comp Phys Comm 91 (1995) 43-56
14. van Aalten D.M., Bywater R., Findlay J.B., Hendlich M., Hooft R.W., and Vriend G. Prodrg, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J Comput Aided Mol Des 10 (1996) 255-262
15. Schüttelkopf A.W., and van Aalten D.M. Prodrg: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60 (2004) 1355-1363
16. Golovin A., and Polyakov N. DNA/RNA records for OPLS force field in GROMACS format (March 08, 2005). http://rnp-group.genebee.msu.su/3d/oplsa http://rnp-group.genebee.msu.su/3d/oplsa ff.html
17. Case D.A., Cheatham T.E., Darden T., et al. The amber biomolecular simulation programs. J Comput Chem 26 (2005) 1668-1688
18. Ponder J.W., and Case D.A. Force fields for protein simulations. Adv Protein Chem 66 (2003) 27-85
19. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., and Klein M.L. Comparison of simple potential functions for simulating liquid water. J Chem Phys 79 (1983) 926-935
20. Hockney R.W., Goel S.P., and Eastwood J.W. Quiet high-resolution computer models of a plasma. J Comp Phys 14 (1974) 148-158
21. Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., DiNola A., and Haak J.R. Molecular dynamics with coupling to an external bath. J Chem Phys 81 (1984) 3684-3690
22. Darden T., York D., and Pedersen L. Particle mesh Ewald: an N*log(N) method for Ewald sums in large systems. J Chem Phys 98 (1993) 10089-10092
23. Essmann U., Perera L., Berkowitz M.L., Darden T., Lee H., and Pedersen L.G. A smooth particle mesh Ewald method. J Chem Phys 103 (1995) 8577-8593
24. Amadei A., Linssen A.B., and Berendsen H.J. Essential dynamics of proteins. Proteins 17 (1993) 412-425
25. Humphrey W., Dalke A., and Schulten K. VMD - visual molecular dynamics. J Mol Graph 14 (1996) 33-38
26. Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph 8 (1990) 52-56
27. Hess B. Convergence of sampling in protein simulations. Phys Rev E 65 (2002) 031910
28. Welford B.P. Note on a method for calculating corrected sums of squares and products. Technometrics 4 (1962) 419-420
29. Knuth D.E. The art of computer programming. seminumerical algorithms. 3rd ed. 2 (1997), Addison-Wesley Longman Publishing Co., Inc.
30. Hess B. Similarities between principal components of protein dynamics and random diffusion. Phys Rev E 62 (2000) 8438-8448
31. Persistence of Vision Raytracer (POV-Ray), http://www.povray.org.
32. Minton A.P., and Wilf J. Effect of macromolecular crowding upon the structure and function of an enzyme: glyceraldehyde-3-phosphate dehydrogenase. Biochemistry 20 (1981) 4821-4826
33. Tokuriki N., Kinjo M., Negi S., et al. Protein folding by the effects of macromolecular crowding. Protein Sci 13 (2004) 125-133
34. Prongay A.J., et al. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. J Med Chem 50 (2007) 2310-2318